Linked Life Data

18464108

Source:http://linkedlifedata.com/resource/pubmed/id/18464108

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2008-5-8
pubmed:abstractText
Allogeneic stem cell transplantation (AlloSCT) is the only potentially curative therapy for chronic lymphocytic leukemia (CLL), but high transplant-related morbidity and mortality rates limit its widespread use. Data on the long-term toxicity of alloSCT in this group of patients are lacking. We evaluated response and survival rates as well as measures of quality of life (QOL) in 13 patients with CLL, selected for high-risk progressive disease from the transplant database at the Royal Melbourne Hospital. Seven of 13 patients (54%) achieved a complete remission (CR), of whom four remained in continuous CR at 30-77 months post-transplant. The event-free and overall survival rates were 31% and 38% respectively at 5 years. The transplant-related mortality was 31% at 2 years. Three of 5 patients still alive at last follow-up have resumed part- or full-time employment. AlloSCT is a feasible salvage therapeutic strategy and can provide meaningful disease-free survival and quality of life for some patients with high-risk refractory CLL.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1029-2403
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
49
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
896-901
pubmed:dateRevised
2008-11-4
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Long-term toxicity of allogeneic stem cell transplantation in fludarabine-refractory chronic lymphocytic leukemia.
pubmed:affiliation
Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Australia.
pubmed:publicationType
Journal Article